Part-Time
Neurotherapeutics platform combining sensors, software, music
No salary listed
Portland, ME, USA
Hybrid
See people who can refer or advise you
MedRhythms develops neurotherapeutic solutions that aim to improve walking, mobility, and related brain health for people with neurologic injuries and diseases. Its core product is a proprietary platform that combines sensors, software, and music, guided by neuroscience, to target neural circuits and support functional recovery. The system works by delivering music-assisted therapy through sensor-driven feedback and software-based protocols that engage brain networks involved in movement, with services sold to healthcare providers and patients. What sets MedRhythms apart is its patented, integrated technology that merges music, sensors, and neuroscience into a single therapeutic approach, along with a multidisciplinary, nationwide team and a focus on translating neuroscience into practical mobility outcomes. The company’s goal is to improve life for individuals with movement disorders by restoring mobility and promoting brain health through accessible, clinician-supported therapies.
Company Size
51-200
Company Stage
Late Stage VC
Total Funding
$61.1M
Headquarters
Portland, Maine
Founded
2013
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Paid Vacation
Paid Sick Leave
Parental Leave
Flexible Work Hours
Professional Development Budget
PORTLAND, Maine, July 7, 2025 /PRNewswire/ - MedRhythms, Inc., a company pioneering the development of next-generation neurotherapeutics to improve walking, mobility and related functional outcomes, and creator of the world's first prescription music platform, announced the appointment of Larry Jasinski as Chief Executive Officer, effective immediately.
CDVCA has made a follow-on investment in MedRhythms, a digital therapeutics company focused on improving mobility and quality of life for individuals with neurological conditions like strokes or multiple sclerosis. The investment supports MedRhythms' FDA-regulated prescription therapy technology and its commitment to advancing neurorehabilitation. Coastal Ventures 5, a CDVCA member fund, also participated in the investment.
PORTLAND, Maine, April 2, 2025 /PRNewswire/ -- MedRhythms today announced that Movive™, the company's neurorehabilitation system to support gait rehabilitation and motor function in adults with Parkinson's disease (PD), is now available for order within the U.S. Department of Veteran Affairs (VA) through the General Services Administration Multiple Award Schedule (GSA MAS), and also the Federal Supply Schedule (FSS)
Under his leadership, MedRhythms has raised over $60 million in capital, was recognized as an FDA breakthrough technology, and created high-paying jobs - all while advancing cutting-edge technology that serves people nationwide.
PORTLAND, Maine, March 6, 2025 /PRNewswire/ -- MedRhythms today announced that MR-005, the company's neurorehabilitation system to support gait rehabilitation and motor function in adults with Parkinson's disease (PD), has been listed as a Class II, Rx-only medical device with the U.S. Food and Drug Administration (FDA). The company unveiled the system's brand name: Movive™."Movive leverages the well-researched power of rhythmic auditory stimulation (RAS) for people with PD and is the second device to launch from MedRhythms' proprietary platform," said Brian Harris, Co-Founder and CEO of MedRhythms. "This is an exciting step for MedRhythms as we advance our mission to use music to address significant mobility challenges for people with neurologic injury and disease, including PD. We look forward to Movive's potential to support gait rehabilitation in PD, addressing a significant need."PD is the fastest growing neurodegenerative disease in the world. According to the Parkinson's Foundation , nearly one million Americans have PD, including 110,000 Veterans, making it the second most common neurodegenerative disease